Evolv Technology Q3 2026 Earnings Call - EVOLV TECHNOLOGIES HOLDINGS INC

Financial Performance:

• Q3 2026 revenue reached a record $47.3 million, a 10% year-over-year increase; normalized growth was approximately 18-19% excluding a legacy large contract.
• Full-year 2026 revenue guidance raised to $182-$195 million (midpoint $183M), representing 25-27% YoY growth; ARR guidance reaffirmed at $148-$150 million.
• Recurring revenue hit $32.5 million (69% of total revenue), driving ARR growth of 20% YoY to $140.5 million, outpacing revenue growth.
• Gross margin on a GAAP basis was 49.7% (consistent YoY); product gross margin declined to 8.7% due to pricing shifts, while subscription (59.8%) and services (72.6%) margins expanded.
• Adjusted EBITDA margin was 10% in Q3 (down from 12% YoY) due to strategic investments; full-year 2026 margin expected in the high single digits.
• Free cash flow was positive $3.2 million in Q3; operating cash flow increased $14.5 million YoY to $18 million.
• Remaining Performance Obligation (RPO) grew 12% YoY to $325.8 million (1.7x full-year revenue outlook), with 4% sequential growth.
• Net Revenue Retention (NRR) stood at 108% for the quarter.
• Balance sheet strengthened with cash, equivalents, and restricted cash rising $3.5 million to $66.9 million.

Guidance and Future Outlook:

• 2027 revenue growth guidance set at 20%+, despite a 3-4% headwind from pricing model changes shifting revenue from upfront product to recurring streams.
• Long-term five-year framework (2026-2031) targets a 25% compound annual revenue growth rate.
• ARR growth is expected to sustainably outpace revenue growth in 2027 as the recurring mix expands.
• Management expects RPO to continue growing healthily, with an embedded gross margin profile of approximately 66% on future recognized revenue.
• 2027 operating plan anticipates modest expansion in adjusted EBITDA margins, funded by gross profits and existing balance sheet.
• Full-year 2026 unit deployment expected to exceed 2027 volume, though incremental units arriving in H2 2027 will limit immediate recurring revenue recognition.

Business Segments and Product Lines:

• Education: Deployed in 28 of the top 100 US school districts and 1,900+ buildings; added a dozen new K-12/Higher Ed customers in Q3.
• Healthcare: Represents 23% of units booked in Q3 (up from 18% LTM); serves 800+ hospital buildings including all top 10 networks; California regulations driving adoption by March 2027.
• Sports/Entertainment: Added new venues (Climate Pledge Arena, Prudential Center) and expanded collegiate presence (Tennessee, Memphis).
• Corporate: Serves 40+ Fortune 500 companies; added three new Fortune 500 customers in Q3.
• Product Innovation: Launched Expedite 3.0 (enhanced bag alert context and sensitivity); Express 11.0 in beta (improved detection, lower alert rates); backward compatibility ensures existing base benefits.
• Cross-Sell: ~9% of customer base uses Expedite; 88% of new Expedite customers also purchased Express; ~60% of Q3 bookings came from existing customers.

Market and Competitive Landscape:

• Total addressable market estimated at 700,000 doorways; current penetration is <5% (~10,000 units deployed).
• Technology differentiators include proprietary sensor hardware, AI models trained on proprietary data, and integrated software services; not replicable by generic AI tools.
• Competitive advantages cited: high throughput, threat isolation capabilities, and data insights.
• International expansion is in early stages (~4% of 2025 revenue) and faces regulatory hurdles regarding hardware (ionizing radiation) and data privacy, but is a targeted future growth area.

Risks and Challenges:

• Pricing Model Transition: A 3-4% headwind in 2026 and 2027 revenue growth rates due to shifting contract value from one-time product to recurring revenue.
• Hardware/Regulatory Compliance: International expansion requires navigating varying hardware safety and radiation regulations.
• Sales Ramp: New sales hires take multiple quarters to reach full productivity, delaying immediate revenue impact.
• Seasonality: First half of 2027 faces difficult comparisons to H1 2026 which benefited from a six-month direct fulfillment model period and backlog shipments.
• Operational Investments: Increased spending on R&D, sales, and SOX remediation impacts short-term margins.

Management Commentary and Tone:

• Tone is highly confident, emphasizing a "scalable, high-growth" business with consistent performance.
• Management views the pricing shift as beneficial for long-term value and predictability, despite short-term revenue recognition headwinds.
• CEO highlighted the "real impact" of the tech, citing over 5 billion people screened and 2.2 million weapons tagged since 2021.
• CFO and CEO emphasized discipline in capital allocation, funding growth from operating cash flow rather than debt.
• Strong belief in the "Expedite + Express" combination as a key lever to lower staffing friction and drive broader market adoption.

Analyst Questions and Answers:

• Mix & Seasonality (Craig Hallam): Q3 deployment mix was ~50% subscription / 50% purchase; expected to remain ~50-50 in 2027; no significant H1/H2 seasonality expected.
• ARR Acceleration: ARR growth accelerating (20%) vs revenue (10%) due to pricing changes moving $8k per unit from one-time to ARR; full impact materializes over four-year contract term.
• Bookings & RPO (Northland): ~60% of bookings from existing customers; total install base >10,000 units; RPO growth expected to remain healthy as mix shifts to recurring.
• Sales Capacity (Lake Street): Investments prioritized in frontline sellers for North America, with future international expansion pending regulatory clearances.
• International (Leidenberg Tholman): International included in 2027 guidance but currently small contributor; long-term upside dependent on regulatory compliance.
• EBITDA Margin (Leidenberg Tholman): Q3 Q4 comparison reflects product mix (purchase vs subscription) and seasonality; no drastic change in investment run-rate, continued focus on profitable growth.

Other Key Points:

• Investor Relations plans to attend Craig Hallam Alpha Select, UBS Global Technology, and Northland Capital conferences.
• Non-GAAP measures used include adjusted gross margin, adjusted EBITDA, and free cash flow; forward-looking non-GAAP reconciliations unavailable.
• 51 new customers added in Q3; 23% of new healthcare bookings represented the Universal Health Services system.
• Management expects to fund growth entirely from gross profits and existing cash, maintaining a disciplined capital structure.